°øÁö : µµÄìÁõ±Ç°Å·¡¼Ò JASDAQ ½ºÅÄ´Ùµå ½ÃÀå ½Å±Ô »óÀå °ü·Ã ¾È³»

Global Information
ȸ»ç¼Ò°³ | ¹®ÀÇ | ºñ±³¸®½ºÆ®

Anti-Infective Drug News

¸®¼­Ä¡»ç Fitch Solutions, Inc.
¹ßÇàÁ¤º¸ 12 ȸ/³â »óǰ ÄÚµå 6035
ÆäÀÌÁö Á¤º¸ ¿µ¹®
°¡°Ý
US $ 1,315 £Ü 1,493,000 PDF (Single User License)


Anti-Infective Drug News Anti-Infective Drug News
¹ßÇàÁ¤º¸ : 12 ȸ/³â ÆäÀÌÁö Á¤º¸ : ¿µ¹®

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹®¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹®¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Ç×°¨¿°¾àÀº 20³â Àü¿¡´Â ±ØÈ÷ ÇÑÁ¤µÈ ºÐ¾ß¿¡¼­ÀÇ Ä¡·á¾àÀ¸·Î °£ÁֵǾúÁö¸¸, ÃÖ±Ù¿¡´Â ¿¡ÀÌÁî¿Í ½ÅÇü ÀÎÇ÷翣ÀÚ µîÀÇ Ä¡·á¾àÀ¸·Î Æø ³ÐÀº ÁÖ¸ñÀ» ²ø¾ú½À´Ï´Ù. ÃÖ÷´Ü ºñÁî´Ï½ºÀÇ Á¶»ç ºÐ¼®À» Àü¹®À¸·Î ÇÏ´Â Espicom Business Intelligence (º»»ç£º¿µ±¹) ¿¡¼­´Â Ç×°¨¿°¾à¿¡ °üÇØ ÀÌ È¸»ç°¡ ÀÚ¶ûÇÏ´Â µ¶ÀÚÀû Á¶»ç¿¡ ±Ù°ÅÇØ Æø ³Ð°Ô ¼öÁýÇÑ °´°üÀû µ¥ÀÌÅÍ¿Í ÃֽŠÁ¤º¸¸¦ Á¤¸®ÇÑ ¿ù°£ ´º½º·¹ÅÍ "Anti-Infective Drug News: Monitoring Antibiotic & Antiviral Drug Developments Worldwide"¸¦ ¹ßÇàÇϰí ÀÖ½À´Ï´Ù.

º» ´º½º·¹ÅÍ¿¡¼­´Â Á¦¾à ¾÷°è µ¿ºÐ¾ßÀÇ °³¹ß µ¿ÇâÀ» ¾Ë±â ½±°Ô 36ÆäÀÌÁö ÀÌ»óÀ¸·Î ü°èÈ­ÇØ¼­ °£ÇàÇϰí ÀÖ°í£¬°³¿ä´Â ´ÙÀ½°ú °°ÀÌ µÇ¾îÀÖ½À´Ï´Ù.

  • Ç×°¨¿°¾à ºÐ¾ß ´º½º
    ÀÌÇϸ¦ Æ÷ÇÔÇØ¼­ Á¾·ùº°·Î ³ª´« ¿¬±¸°³¹ß, Á¦Ç°, °è¾à°ü·Ã ´º½º
    • Ç×±Õ
    • Ç×»ê±Õ
    • Ç× ¹ÙÀÌ·¯½º
    • HIV/¿¡ÀÌÁî
    • ±â»ýÃæ ´ëÃ¥
  • Àü¹ÝÀû µ¿Çâ ´º½º
    µ¿ºÐ¾ßÀÇ ¾àǰ Àü¹ÝÀ» ¸Á¶óÇÑ ¿¬±¸°³¹ß, Á¦Ç°, °è¾à°ü·Ã ´º½º
  • µ¿¸Í ¸ñ·Ï
    ¿¹Á¤µÈ ȸÀÇ ¹× ¼¼¹Ì³ª µîÀÇ À̺¥Æ® ¸ñ·Ï
kyj 02.03.15

BMI View: A number of developments within the European hepatitis C market indicate that the drug pricing battle seen in the US is extending to Europe. European payers have already secured substantial discounts for existing HCV drugs, yet current cost-containment trends in Europe mean that competitive pricing leading to further discounts is welcomed by European payers.

Table of Contents

  • US HCV Drug Pricing Battle To Extend To Europe Antibacterials
  • Agreements
  • Roche/Meiji/Fedora Enter Collaboration For Development Of OP0595
  • Valneva To Acquire Dukoral Vaccine From Crucell
  • SinSa Signs Deal For Technology Platform To Prevent Antibiotic Resistance
  • R&D
  • Aradigm Granted Key Composition Of Matter Patents For Pulmaquin In Europe/Australia
  • Galapagos Secures IWT Grant For Antibiotic Research Antifungals
  • Product Updates
  • FDA Advisory Committee Recommends Cresemba Approval For Invasive Aspergillosis/Mucormycosis
  • R&D
  • Scynexis' SCY-078 Oral Formulation Gains FDA Fast Track Designation Antivirals
  • Agreements
  • Debiopharm Regains Full Rights To Alisporivir Programme
  • Vical/AnGes Collaborate To Develop Therapy Against Ebola
  • Product Updates
  • Prevenar 13 Gains CHMP Positive Opinion For Vaccine-Type Pneumococcal Pneumonia In Adults
  • AbbVie's Viekirax/Exviera Licensed For Use In UK For cHCV
  • Payer Pressure Forces Gilead/AbbVie Drug Pricing Battle To Remain Heated
  • Mylan Launches Lamivudine In US
  • Health Canada Approves Novartis' Fluad Pediatric Flu Vaccine
  • Gilead Likely To Weather The Indian Sofosbuvir Patent Rejection Storm
  • R&D
  • Chimerix Granted US Patent Allowance Covering Brincidofovir
  • Waning Of Ebola Outbreak Could Hamper Vaccine Developments
  • J&J Forms Ebola Vaccine Development Consortia; Secures Funding Corporate Activity
  • Tekmira/OnCore Merge To Create Global HBV Company
  • Merck Completes Tender Offer To Acquire Cubist
  • Court Orders SIGA To Pay Tecovirimat Damages To PharmAthene
  • Moderna Launches New Venture Valera For Infectious Diseases
  • NovaBiotics Raises Funds Via Private Placement
Back to Top
ÀüÈ­ ¹®ÀÇ
F A Q